Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seribantumab in NRG1 fusion positive metastatic pancreatic cancer
NCT04790695Phase 2Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of seribantumab in pancreatic cancer (PC), sponsored by Ottawa Hospital Research Institute. Started Mar 2021; status: completed.
02
Drugs
seribantumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04790695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04790695.